In aggressive breast cancer, RAC3’s specific binding partner CIB1 facilitates the recruitment of RAC3, promoting integrin activation at invasive pseudopodia, thereby regulating adhesion and degradation of the extracellular matrix (ECM) (Wang et al., 2022). Here, RAC3 is linked to breast cancer.